Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Nyxoah ( (NYXH) ) is now available.
On May 30, 2025, Nyxoah SA announced that it received a transparency notification from Vestal Point Capital, indicating an acquisition or disposal of voting securities or rights. As of May 21, 2025, Vestal Point Capital holds 1,809,843 voting rights, representing 4.84% of the total voting rights, just below the 5% threshold. This notification highlights a shift in shareholder structure, which could impact Nyxoah’s governance and decision-making processes.
The most recent analyst rating on (NYXH) stock is a Buy with a EUR19.00 price target. To see the full list of analyst forecasts on Nyxoah stock, see the NYXH Stock Forecast page.
More about Nyxoah
Nyxoah SA is a company operating in the medical technology industry, focusing on the development and commercialization of innovative solutions for the treatment of sleep apnea. The company is known for its implantable neurostimulation devices designed to treat Obstructive Sleep Apnea (OSA) by stimulating the hypoglossal nerve to maintain an open airway during sleep.
Average Trading Volume: 87,776
Current Market Cap: €263.1M
For an in-depth examination of NYXH stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue